FDA halts Allogene blood cancer trials after patient found to have ‘chromosomal abnormality’

Allogene Therapeutics said the FDA had placed a hold on its clinical trials after a patient with blood cancer treated with its off-the-shelf CAR-T cell therapy was found to have a “chromosomal abnormality.”